Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
10 studies found for:    BMS-663513
Show Display Options
RSS Create an RSS feed from your search for:
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
Condition: B-Cell Malignancies
Interventions: Biological: Urelumab;   Biological: Rituximab
2 Not yet recruiting A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Elotuzumab;   Drug: Lirilumab;   Drug: Urelumab
3 Recruiting Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Condition: Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma
Intervention: Drug: Urelumab (BMS-663513)
4 Recruiting Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
Conditions: Colorectal Cancer;   Head and Neck Cancer
Interventions: Biological: Urelumab;   Biological: Cetuximab
5 Recruiting Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma
Conditions: Advanced Solid Tumors;   Advanced B-cell NHL
Interventions: Biological: Urelumab;   Biological: Nivolumab
6 Terminated A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)
Condition: Non Small Cell Lung Cancer
Intervention: Drug: BMS-663513
7 Terminated A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies
Condition: Advanced Solid Malignancies
Intervention: Drug: BMS-663513
8 Terminated Study of BMS-663513 in Patients With Advanced Cancer
Condition: Tumors
Intervention: Drug: BMS-663513
9 Withdrawn Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma
Condition: Melanoma
Interventions: Drug: AntiCD137;   Drug: Ipilimumab
10 Completed Phase II, 2nd Line Melanoma - RAND Monotherapy
Condition: Melanoma
Intervention: Drug: Anti-CD137 (4-1BB) (BMS-663513)

Indicates status has not been verified in more than two years